31 December 2013 - A treatment for an aggressive type of cancer that develops in the body's immune system has been given the green light in final draft guidance from the NICE. It says the drug pixantrone (Pixuvri, made by Cell Therapeutics) should be funded by the NHS to treat certain people with aggressive non-Hodgkin's B-cell lymphoma.

For more details, go to: http://www.nice.org.uk/newsroom/pressreleases/NICEYesNonHodgkinsLymphomaTreatmentFinalDraftGuidance.jsp